Compared to untreated MS patients, the FTY group showed a reduced B cell frequency, NAT treatment resulted in a significant increase of B cells, and both DMF and GA had no detectable effect (Fig. 1a, b). The gene discussed is BRD2; the disease is myeloid sarcoma.